



Company Fact Sheet

- About:** SPR Therapeutics is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence in peripheral nerve stimulation for the treatment of pain, SPR has demonstrated commercial demand in underserved peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR's Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients' lives by providing them with a minimally-invasive, drug-free, surgery-free solution to manage their acute and chronic pain.
- Offices:** Cleveland, Ohio (Headquarters)
Minneapolis, Minnesota
Chapel Hill, North Carolina
- Executive Team:** Maria Bennett, Founder, President and CEO
Joseph Boggs, PhD, Chief Scientific Officer, and Senior Vice President, Research & Development
Mark Stultz, Senior Vice President, Market Development
David Youngberg, Senior Vice President, Sales
Ben Austin, Chief Financial Officer
- Key Advisors:** Peter Staats, MD, MBA, DABA, ABIPP, FIPP, Chief Medical Advisor
Warren Grill, PhD, Chief Scientific Advisor
Marc Huntoon, PhD, Director of Medical Affairs
- Non-dilutive Funding:** SPR Therapeutics has been awarded over \$30M in Federal grants and contracts from the U.S. Department of Defense as well as the National Institute of Health to support prior and ongoing clinical trials and device advancements.
- Product Overview:** The Company's SPRINT Peripheral Nerve Stimulation (PNS) System is the only percutaneous PNS device FDA-cleared for up to 60 days for both chronic and acute pain, including post-operative and post-traumatic pain.
- The SPRINT PNS System works by implanting a thin lead wire, the MicroLead™, typically under image-guidance, to target a peripheral nerve. The MicroLead is connected to a wearable external generator that sends small electrical pulses to the nerve for up to 60 days after which time the lead is withdrawn. In multiple studies, the SPRINT PNS System has demonstrated the ability to deliver effective and sustained improvements in pain and function after the MicroLead has been withdrawn. Physicians have prescribed the SPRINT system to treat multiple pain conditions including post-amputation pain, inoperable shoulder and knee joint pain, chronic low back pain, complex regional pain syndrome (CRPS), and post-operative pain following joint replacement and surgical reconstruction (partial listing). Several post-market clinical trials are underway.
- Indication:** The SPRINT® Peripheral Nerve Stimulation (PNS) System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; symptomatic relief of post-

operative pain. The SPRINT® PNS System is not intended to treat pain in the region innervated by the cranial and facial nerves.

Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

For additional information regarding safety and efficacy, visit [SPR Safety Information](#).

Website: www.SprTherapeutics.com

Company Contact: Michelle McDonald
Vice President - Marketing
mmcdonald@sprtherapeutics.com
844.378.9108

Media Contact: Dave Folkens
Public Relations
dfolkens@sprtherapeutics.com
612-978-6547